8-K: Allogene Therapeutics Reports Promising Data and Outlines Key Milestones for AlloCAR T Programs

Allogene Therapeutics announces fourth quarter and full year 2024 financial results, highlighting progress in its AlloCAR T programs and anticipating key data milestones in 2025.

Summary

• Allogene Therapeutics reported its fourth quarter and full year 2024 financial results and provided a business update on its AlloCAR T programs.
• The company's pivotal Phase 2 ALPHA3 trial for cema-cel in LBCL is progressing with site activation and patient enrollment, with lymphodepletion selection and futility analysis expected around mid-2025 and primary EFS data expected around YE 2026.
• A potential BLA submission for cema-cel is targeted for 2027.
• The FDA cleared the IND for ALLO-329 in autoimmune diseases, with trial initiation targeted for mid-2025 and proof-of-concept data expected around YE 2025.
• Positive Phase 1 data for ALLO-316 in RCC was presented, and enrollment in the Phase 1b expansion cohort is complete, with data expected mid-2025.
• Allogene ended Q4 2024 with $373.1 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2026.
• The company expects a decrease in cash, cash equivalents, and investments of approximately $170 million in 2025.
• GAAP Operating Expenses are expected to be approximately $250 million, including estimated non-cash stock-based compensation expense of approximately $50 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, FDA clearance for ALLO-329, and a cash runway extending into the second half of 2026. However, the net losses and projected decrease in cash temper the overall sentiment.

Positives

• The ALPHA3 trial is the first pivotal trial to offer CAR T to potentially eradicate MRD to improve cure rates in LBCL.
• ALLO-329 offers a novel approach to treating autoimmune diseases as the first allogeneic CD19/CD70 dual CAR T product.
• ALLO-316 is the only allogeneic CAR T therapy to show potential in solid tumors.
• Allogene received Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 for adult patients with advanced or metastatic RCC.

Negatives

• The company reported a net loss of $59.9 million for the fourth quarter of 2024 and $257.6 million for the full year.
• The company expects a decrease in cash, cash equivalents, and investments of approximately $170 million in 2025.

Risks

• The company's success depends on the success, cost, and timing of its product development activities and clinical trials.
• The regulatory approval process poses risks, and the company may face potential delays or difficulties in product manufacturing.
• Competition from other biopharmaceutical companies and the ability to obtain additional funding are also risks.

Future Outlook

Allogene expects its cash runway to fund operations into the second half of 2026 and anticipates key data milestones in 2025 for its AlloCAR T programs.

Management Comments

• In 2024, we focused on delivering on our bold strategy to achieve what no CAR T has accomplished before, said David Chang, M.D., Ph.D., President, Chief Executive Officer, and Co-Founder of Allogene.
• We believe 2025 will be the year allogeneic CAR T broadly begins to demonstrate its potential to surpass autologous CAR T therapy by reaching more patients with greater accessibility.

Industry Context

Allogene is positioning itself as a leader in the development of allogeneic CAR T therapies, aiming to overcome the limitations of autologous CAR T therapies by providing off-the-shelf products that are more accessible and scalable.

Comparison to Industry Standards

• The company's Phase 1 ALPHA/ALPHA2 trials of cema-cel in relapsed/refractory LBCL demonstrated durable responses comparable to approved autologous CD19 CAR T therapies, such as Novartis's Kymriah and Gilead's Yescarta.
• The development of ALLO-329 for autoimmune diseases represents a novel approach compared to existing therapies, which primarily target individual components of the immune system.
• ALLO-316 is the only allogeneic CAR T therapy to show potential in solid tumors, setting it apart from other CAR T therapies that are primarily focused on hematological malignancies.

Related Party Transactions

• The company reported collaboration revenue related to a related party.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and progress in clinical trials.
• Employees are impacted by the company's operations and development programs.
• Patients may benefit from the development of new AlloCAR T therapies.
• Suppliers and creditors are impacted by the company's financial position and operations.

Next Steps

• Initiate the RESOLUTION trial for ALLO-329 in autoimmune diseases in mid-2025.
• Announce data from the Phase 1b expansion cohort of ALLO-316 in mid-2025.
• Conduct lymphodepletion selection and futility analysis for the ALPHA3 trial around mid-2025.
• Announce primary EFS data from the ALPHA3 trial around YE 2026.
• Submit a potential BLA for cema-cel in 2027.

Key Dates